← BackICU MEDICAL INC/DE · Surgical & Medical Instruments & ApparatusICUI
Low riskNext report: Around Nov 5 (est.)
The short versionA profitable company with steady sales. Institutions are adding.
Going well
- Profitable
- Brings in more cash than it spends
Money moves
- No insider buying or selling in the last 30 days
- Institutions added 3.7% to their holdings in the quarter ending June 2026 (161 bought, 113 sold)
Facts from SEC filings, not a recommendation.
What the price means
Price as of Oct 26
$166.08-0.3% that day
- Company value
- $4.2B
- Share price times all shares
- Price vs profit (P/E)
- 139.6x
- You pay about $140 for each $1 of yearly profit
- Price vs sales
- 1.9x
- Company value is 1.9 times a year of sales
- Cash vs value
- 7%
- Cash as a share of company value
- Debt vs value
- 31%
- Debt as a share of company value
From ICUI's last IEX trade and its SEC filings (profits and sales over the last four quarters). A starting point for research, not a verdict.
The business over time
Last 12 quarters, from SEC filings
Sales, Jun '26$551.7M+0.5% vs a year earlier
Sep '23Tap a barJun '26
Last 12 months: $2.2B, down 9.0% from the 12 months before. Over 5 years, sales grew about 12% a year.
Business quality
The checklist Warren Buffett-style investors use. Annual numbers for 2025.- MissReturn on equity 15%+Earns a lot on the money owners have in the business.0.0%
- MissDebt under half of equityNot relying on borrowed money.0.60x equity
- MissNet margin 10%+Keeps at least 10 cents of profit from each dollar of sales.0.0%
- MissProfitable every yearSteady profits, not one good year.7 of 10 years
- PassFree cash flow positiveBrings in more cash than it spends to run and grow.$91.8M
- MissShare count not growingNot diluting owners. Falling means buybacks.+4.3% in 3 years
- MissGross margin 40%+Pricing power: sells for well above what it costs to make.36.8%
- Revenue
- $2.2B
- -6.3% vs prior year
- 5-year growth
- +11.9%/yr
- revenue, per year
- Total debt
- $1.3B
- 0.60x equity
- Current ratio
- 2.39x
- short-term assets / bills due
From annual reports filed with the SEC. A checklist is a starting point for research, not a verdict.
Latest quarter
Quarter ended Jun 30, 2026- Revenue
- $551.7M
- +0.5% YoY
- EPS
- $0.76
- vs $1.43
- Op. margin
- 7.1%
- +5.2 pts
- Gross margin
- 42.6%
- +4.7 pts
- Free cash flow
- $61.6M
- Share count
- +1.4%
- vs a year ago
Insider rating
Last 90 days
No open-market insider buys or sells in the last 90 days.
Weekly insider trendNo trades to chart yet.
Filing buzz
Last 7 days vs normal
0/ 100
- This week
- 0
- Normal week
- 1.4
- vs normal
- 0.0x
SEC filings of any kind. 50 means a normal week.
Institutional ownership
▲Accumulating+3.7%Institutions added 3.7% to their holdings. 161 bought, 113 sold.
Shares held by institutions26.0M
Sep '24Jun '26
Share count growthYearly rate, last 3 years
+1.2%Cash runwayAt last year's cash burn
Cash flow positiveDebt to equityLatest balance sheet: debt compared with what owners have
0.6x · $1.2B debtShares outstandingLatest reported
25MNext reportAround Nov 5 (est.)Estimated from the same quarter last year
- Results filedAug 6
- Results filedMay 7
- Results filedFeb 19
- Results filedNov 6, 2025
- Results filedAug 7, 2025
Insider trades
Open-market buys and sells, last 90 days
No open-market buys or sells in 90 days. Grants and option exercises are left out.
"Owns after" is the insider's holding right after the trade. Pre-planned (10b5-1) sales are set up months ahead, a weaker signal.
Latest filings
Straight from SEC EDGAR
Planned insider saleSep 3 · Form 144 ↗SoldVirginia Ruth SanzoneVP, General Counsel
4,856 shares at $168.69 avg ($167.67 to $171.52) · $819K
- -25% of holdings
- Now owns 14,604 shares
- Pre-planned sale (10b5-1)
- 4 transactions
- Filed same day
Planned insider saleSep 1 · Form 144 ↗SoldBrian Michael BonnellChief Financial Officer
6,381 shares at $175.00 · $1.1M
- -10% of holdings
- Now owns 56,062 shares
- Pre-planned sale (10b5-1)
- Filed same day
Planned insider saleAug 31 · Form 144 ↗SoldBrian Michael BonnellChief Financial Officer
9,307 shares at $172.79 avg ($171.05 to $173.91) · $1.6M
- -13% of holdings
- Now owns 62,443 shares
- Pre-planned sale (10b5-1)
- 4 transactions
- Filed same day
5%+ holder update (passive)Aug 14 · Form SCHEDULE 13G/A ↗5%+ holder update (passive)Aug 13 · Form SCHEDULE 13G/A ↗Planned insider saleAug 13 · Form 144 ↗SoldDaniel WoolsonVP, GM-Infusion Capital
5,417 shares at $181.33 · $982K
- -24% of holdings
- Now owns 17,062 shares
- Not a pre-planned sale
- Filed same day
Planned insider saleAug 12 · Form 144 ↗SoldBen SousaChief Information Officer
2,250 shares at $178.32 · $401K
- -42% of holdings
- Now owns 3,076 shares
- Not a pre-planned sale
- Filed same day
Planned insider saleAug 11 · Form 144 ↗Planned insider saleAug 11 · Form 144 ↗SoldElisha W FinneyDirector
378 shares at $182.48 · $69K
- -7% of holdings
- Now owns 4,871 shares
- Not a pre-planned sale
- Filed same day